The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis

Documenti analoghi

• Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
  di: C. M. Fernández‐Rodríguez, et al.
  Pubblicazione: (2024)
• Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
  di: Nabil Noureddin, et al.
  Pubblicazione: (2024)
• Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
  di: John E. Eaton, et al.
  Pubblicazione: (2024)
• Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
  di: Richie Manikat, et al.
  Pubblicazione: (2024)
• Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)